Manuel Dómine
Grupo Español de Cáncer de Pulmón · 17 works · 239 citations · h-index 7
Top works
- SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
- Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
- Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
- Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy
- Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
- Eritema acral inducido por quimioterapia. Descripción de cuatro casos y revisión de la literatura.
- Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
- Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
- BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
- Linguistic adaptation and validation of the Spanish version of the Memorial Pain Assessment Card (MPAC)
- MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
- P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
- Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016–2025)
- ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
- Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
- Effects of 5-fluorouracil on endothelial nitric oxide synthase in endothelial cells in different states of confluence